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Chemerin is a protein ligand for the G protein-coupled receptor CMKLR1 and also binds to
two atypical heptahelical receptors, CCRL2 and GPR1. Chemerin is a leukocyte attractant,
adipokine, and antimicrobial protein. Although chemerin was initially identified as a highly
expressed gene in healthy skin keratinocytes that was downregulated during psoriasis, the
regulation of chemerin and its receptors in the skin by specific cytokines and microbial fac-
tors remains unexplored. Here we show that chemerin, CMKLR1, CCRL2 and GPR1 are
expressed in human and mouse epidermis, suggesting that this tissue may be both a
source and target for chemerin mediated effects. In human skin cultures, chemerin is signifi-
cantly downregulated by IL-17 and IL-22, key cytokines implicated in psoriasis, whereas it is
upregulated by acute phase cytokines oncostatin M and IL-1β. Moreover, we show that
human keratinocytes in vitroand mouse skin in vivorespond to specific microbial signals to
regulate expression levels of chemerin and its receptors. Furthermore, in a cutaneous infec-
tion model, chemerin is required for maximal bactericidal effects in vivo. Together, our find-
ings reveal previously uncharacterized regulators of chemerin expression in skin and
identify a physiologic role for chemerin in skin barrier defense against microbial pathogens.
Introduction
Chemerin, also known as tazarotene induced gene 2 (Tig2) or retinoic acid receptor responder
protein 2 (RARRES2), is a broadly expressed leukocyte attractant ligand for serpentine, G pro-
tein-associated receptor CMKLR1 (chemokine-like receptor 1) [1,2,3]. CMKLR1+ plasmacy-
toid dendritic cells (pDCs), macrophages and NK cells are critical in bridging the innate and
adaptive immune responses [3,4,5,6]. Chemerin is secreted as an inactive precursor protein
(Chem163S, with number and capital letter referring to the terminal amino acid position and
single amino acid code, respectively). Chem163S can be converted to chemotactically active
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isoforms, such as Chem157S, through posttranslational carboxyl-terminal processing by a vari-
ety of proteinases [2,7,8,9].
Interest in chemerin has surged in the last few years as chemerin, in addition to its chemo-
tactic function, was reported to regulate adipocyte differentiation [10], angiogenesis [11],
osteoblastogenesis [12], myogenesis [13], and glucose homeostasis [14,15,16].
In addition to CMKLR1, two additional heptahelical receptors, GPR1 and CC-motif chemo-
kine receptor-like 2 (CCRL2), bind chemerin with low nanomolar affinities similar to
CMKLR1 [17,18]. However, among these receptors only chemerin binding to CMKLR1 trig-
gers cell migration, intracellular calcium mobilization, and β-arrestin2 association and receptor
internalization, all features common to classical G protein-coupled receptors. In contrast, che-
merin binding to GPR1 triggers β-arrestin2 association and receptor internalization: whether it
triggers intracellular calcium signaling is unclear [2,17]. The in vivo function of GPR1 remains
relatively obscure, although recent studies using GPR1-deficient mice implicate the receptor in
regulating glucose homeostasis during obesity [19]. CCRL2 regulates chemerin concentrations
by sequestering secreted chemerin, concentrating it on the cell surface and presenting it to ad-
jacent CMKLR1+ cells [18,20,21].
Although fat tissue and liver have been confirmed by multiple groups as key sites of che-
merin production [22] and possibly responsible for the high nanomolar chemerin levels found
circulating in plasma [23], chemerin is also expressed at epithelial barriers, including skin epi-
dermis [24,25,26,27]. There is regional variation in the distribution of chemerin in healthy and
diseased skin. Whereas chemerin is produced by keratinocytes in healthy skin, it is markedly
downregulated in the epidermis of patients suffering from the autoinflammatory skin disease
psoriasis. In contrast, normal dermis contains little chemerin, but affected psoriatic dermis is a
significant source of chemerin as determined by immunohistochemistry [24,27]. These find-
ings suggest an association between skin dysfunction and altered chemerin levels. We and oth-
ers have previously reported that chemerin likely contributes to pDC recruitment to lesional
psoriatic skin [5,24,28]. In addition, in normal skin, specifically the epidermis, chemerin func-
tions as a potent antimicrobial protein, where it embodies a quantitatively significant fraction
of the anti-bacterial activity of cultured keratinocytes [25]. Despite its roles in host defense and
the pathogenesis of skin disease, the mechanisms underlying chemerin expression in skin re-
main poorly defined. The only known regulator of chemerin expression in epidermis is the
anti-psoriatic synthetic retinoid-tazarotene, which upregulates chemerin level in skin raft cul-
tures [27].
Here we show that epidermal chemerin represents an important source of this protein in
the skin under steady-state conditions and is significantly downregulated by cytokines impli-
cated in psoriasis, whereas it is markedly upregulated by bacteria and acute phase mediators.
Materials and Methods
Materials
Human recombinant OSM, IL-1β, IL17 and IL22 were purchased from R&D Systems, whereas
E. coli-derived LPS from Sigma-Aldrich. S. aureus ATCC 35556 and E. coliHB101 were ob-
tained from DSMZ. Bacteria were grown in tryptic soy broth (TSB) (Sigma) to mid-logarithmic
phase and used for subsequent experiments at 1x107 colony-forming units (CFU). When indi-
cated bacteria were heat-killed by incubation of 107CFU bacteria/100 microl PBS at 85°C for
20 min., or were incubated with bacteriocidic concentration of ampicilin (1 μg/ml) for 24h/
48h.
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Mice
Female or male 8–12 weeks old C57BL6 mice and chemerin-deficient mice on C57BL6 back-
ground, as well as WT Balb/C mice, CMKLR1KO [29], CCRL2KO [18] or double CMKLR1/
CCRL2KO mice on Balb/C background were used in these studies. The chemerin KO mice
used for this research project were generated by the trans-NIH Knock-Out Mouse Project
(KOMP) and obtained from the KOMP Repository (www.komp.org). NIH grants to Veloci-
gene at Regeneron Inc (U01HG004085) and the CSD Consortium (U01HG004080) funded the
generation of gene-targeted ES cells for 8500 genes in the KOMP Program and archived and
distributed by the KOMP Repository at UC Davis and CHORI (U42RR024244). Mice were
housed under pathogen-free conditions in the animal facility at the Faculty of Biochemistry,
Biophysics and Biotechnology of Jagiellonian University or the Veterans Affairs Palo Alto
Health Care System. Liver, white adipose tissue (WAT) and skin were harvested and subjected
to RT-QPCR or ELISA analysis. Blood was collected in EDTA coated tubes and centrifuged at
2000g for 6 min. Collected plasma was then subjected to ELISA analysis. This study was carried
out in strict accordance with the recommendations in the Guide for the Care and Use of Labo-
ratory Animals of the National Institutes of Health. The protocols 119/2010, 149/2013 and
A3088-01 were approved by the First Local Ethical Committee on Animal Testing at the Jagiel-
lonian University in Krakow or the Institutional Animal Use and Care Committee at the Veter-
ans Affairs Palo Alto Health Care System (AAALAC-accredited facility). All surgery was
performed under ketamine/xylazine anesthesia, and all efforts were made to minimize suffer-
ing. Mice were sacrificed by inhalation of CO2.
Topical skin infection
Mice were anesthetized and a small dorsal area of the skin was shaved and sterilized with etha-
nol. The shaved area was punctured six times at two places using a syringe needle (BDMicro-
lance, 0.3 × 19 mm) (MidMeds). Two rubber rings both with 8-mm inner diameter were
subsequently attached using an ethylcyanoacrylate-based adhesive and the rings were covered
with OpSite (Medisave). 1 × 107 CFU of S. aureus or E. coli in a volume of 50μl (PBS) was
thereafter injected through the OpSite into the cavity formed by the rubber rings. The ring in-
jected with sterile PBS was used as control. Mice were killed after 24h and the skin within the
side of the rings was retrieved for RT-QPCR and ELISA analysis as well as enumeration of
CFU.
Cell culture
All human studies were performed in compliance with ethical protocols KBET/44/B/2011 and
KBET/87/B/2014 approved by the Jagiellonian University Institutional Bioethics Committee.
Declaration of Helsinki protocols were followed. All participants provided their written in-
formed consent to participate in these studies as recommended by the ethical board. Normal
human keratinocytes were isolated from excess skin from donors obtained at the time of cos-
metic surgery for mole removal or during plastic surgery. Donors included 23 healthy individu-
als (age 36±18 years; F:M, 10:13). Skin biopsies were rinsed three times in calcium- and
magnesium-free PBS supplemented with penicillin (5000U/ml) – streptomycin (5mg/ml) (all
from Sigma). After washing, the biopsy was placed in PBS containing dispase (12U/mL, Gibco)
for 16h at 4°C. Next, the epidermis was separated from the dermis with forceps followed by
treatment with 0.05% trypsin with 2 mM EDTA (Sigma) to isolate epidermal cells. Cells were
cultured in serum free KGM-Gold medium (Lonza Group Ltd.) to generate passage 1 cells. The
keratinocytes were then plated at density of 1×105 cells per well on permeable inserts (12-mm-
diameter, 0.4μm pore size; Millipore, Millicell culture inserts) in PCT Epidermal Keratinocyte
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Medium (CellnTec). Cells were cultured at 37°C in presence of 5% CO2 until confluence. Polar-
ized skin structures that resemble in vivo stratified epidermis were generated by air-liquid in-
terface cultures grown in 3D Prime Medium (CellnTec) for 11 days. Cells were than treated
with the indicated factors for 24h or 48h. The final concentration of stimulating factors were
based on previous publications [30,31,32], or for LPS optimized experimentally [from 10ng to
10 μg/ml], and were as follows; OSM 50ng/ml, IL1 10ng/ml, IL17 200ng/ml, IL22 200ng/ml
and LPS 1μg/ml.
Preparation of skin homogenates and epidermis lysates
Skin was homogenized at 100 mg/ml in water containing protease inhibitor (Complete, Roche)
or lysed as described for the epidermis. The epidermis was separated from the dermis as de-
scribed above. Epidermis was then lysed in a RIPA buffer (25mM Tris-HCl, pH 7.6, 150mM
NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitors, passed
through a 40 μm cell strainer and incubated o/n at 4°C. Extracts were centrifuged at 10,000g
for 30 min to remove cellular debris and then normalized based on protein concentration as
determined by BCA assay (Sigma). Lysates were stored at -20°C until used.
RT-QPCR
Total RNA was extracted as previously described [33] and converted to cDNA using NxGen
M-MulV reverse transcriptase (Lucigen) with random primers (Promega). Real time PCR was
performed on the 7500Fast (Applied Biosystems) using SYBR Green I containing universal PC
R master mix (A&A Biotechnology) and primers specific for; human chemerin (5’ TGGAA
GAAACCCGAGTGCAAA-3’, 5’-AGAACTTGGGTCTCTATGGGG), CMKLR1 (5’- ATGGA
CTACCACTGGGTTTTCGGG-3’, 5’-GAAGACGAGAGATGGGGAAACTCAAG-3’),
CCLR2 (5’-CCGTTTCTTAAAAGGCAGTCTGAA-3’, 5’-GTCATACTTGTCACA
TTGCTCTGC-3’), GPR1 (5’-AATGCCATCGTCATTTGGTT-3’, 5’-CAACTGGGCAGTGAA
GGAAT-3’), GAPDH (5’- GAGTCAACGGTTTGGTCGTATTG-3’, 5’- ATGTAGTTGA
GGTCAATGAAGGGG -3’) and beta-2-microglobulin (B2M) (5’- TCAGCAAGGA
CTGGTCTTTCTATC-3’, 5’- GCTTACATGTCTCGATCCCACTTA-3’), as well as mouse
chemerin (5’- CTTCTCCCGTTTGGTTTGATT-3’, 5’- TACAGGTGGCTCCTCTGGAGGA
GT-3’), CMKLR1 (5’-CAAGCAAACAGCCACTACCA-3’, 5’-TAGATGCCGGAGTCGTTG
TAA- 3’), CCLR2 (5’- TTCCAACATCCTCCTCCTTG -3’, 5’- GATGCACGCAACAATACC
AC -3’), GPR1 (5’- AAAAGCTGTTTGAGGCTAGAAAGG -3’, 5’- AGGAAATCTGTTAA
TGTTCTGTGCG -3’), cyclophilin (5’- AGCATACAGGTCCTGGCATCTTGT -3’, 5’- CAAA
GACCACATGCTTGCCATCCA -3’) and ribosomal protein L13a (RPL13A) (5’-CCTCAA
GGTGTTGGATGGGAT-3’, 5’- GTAAGCAAACTTTCTGGTAGGCTTC-3’). The Excel
based application Best-Keeper was used to analyze the expression stabilities of the commonly
used reference genes [34]. Based on this analysis, murine cyclophylin A and RPL13A, or
human B2M and GAPDH were selected as housekeeping genes for normalizing RNA expres-
sion in RT-QPCR. Relative gene expression normalized to geometric mean of these housekeep-
ing genes was calculated using the 2-ΔΔCT method [35,36]. Whenever possible, specificity of
PCR products was verified using KO mice.
ELISA
Chemerin levels in conditioned media or in epidermis lysates was quantified by human or
mouse-specific ELISA. High-binding ELISA strips (Nunc) were coated with mouse-anti-
human chemerin mAbs (MAB23241), or goat-anti-mouse Abs (AF2325) (both from R&D Sys-
tems) in Tris-buffered saline (50 mM Tris-HCl pH 9.5, 150 mMNaCl). The plates were then
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washed with PBS containing 0.1% Tween 20, and nonspecific protein-binding sites were
blocked with 3% BSA in PBS. Human or mouse recombinant chemerin was used as a standard.
Chemerin was detected using biotin-conjugated goat anti-human chemerin Abs (BAF2324) or
biotin-conjugated rat-anti mouse chemerin mAbs (BAM2325) followed by streptavidin-HRP
(BD Science). The reaction was developed with TMB substrate (BD Science).The ELISA detects
both the 163S and 157S chemerin. Alternatively, chemerin in mouse skin homogenates (100%)
and plasma samples (diluted 1/200) was detected by comercially available ELISA (R&D Sys-
tems), according to the manufacturer’s instructions. The levels of chemerin in plasma or skin
homogenates and epidermis extracts were undetectable in chemerin KO mice.
Immunohistochemistry
Epidermal tissues were fixed in 4% formaldehyde and embedded in paraffin. Paraffin 6-μm sec-
tions were then prepared from keratinocyte cultures. Sections were blocked with goat IgG and
stained with the rabbit anti-human chemerin (H-002-52 Phoenix Pharmaceuticals) or control IgG
(normal rabbit IgG, Jackson Immunoresearch) followed by APC-goat anti-rabbit IgG F(ab)2 (Jack-
son Immunoresearch). Blocking and staining were performed in the presence of 0.1% saponin.
The sections were counterstained with Hoechst 33258 (Invitrogen). Images were captured with a
fluorescence microscope (NIKON, Eclipse) and analyzed by NIS elements software (Nikon).
Statistical analysis
For statistical evaluation, one way ANOVA followed by a Bonferroni post hoc test, or two-
tailed Student’s t test was performed.
Results
Expression of chemerin and its receptors in normal skin
Under normal conditions, expression of chemerin mRNA in skin was approximately ten-fold
and six-fold lower compared to liver and white adipose tissue (WAT), respectively (Fig. 1A).
On the other hand, chemerin protein levels in tissue lysates were only two-fold and three-fold
lower compared to liver and WAT, respectively (liver: 190±40 ng/mg total protein; WAT:
267±37 ng/mg; skin: 86±17 ng/mg) (Fig. 1B). When the skin was split into epidermal and der-
mal sheets, chemerin was found primarily in the epidermis (Fig. 1A and B), in agreement with
previous immunohistochemistry results [26], suggesting that chemerin mRNA and protein lev-
els in total skin might be diluted by low expression of chemerin in dermis. Notably, chemerin
protein levels in epidermal isolations (133±41 ng/mg of total protein) were similar to the levels
detected in the liver.
Since chemerin protein levels in tissue lysates might be affected by binding of secreted che-
merin to chemerin receptors [22], we next analyzed expression of CMKLR1, CCRL2, and GPR1.
Although mRNA for all three receptors was present in liver, WAT and skin, CMKLR1 was ex-
pressed most highly inWAT, whereas CCRL2 and GPR1 were expressed most highly in skin
(Fig. 1C-E). CMKLR1and GPR1 expression tended to be higher in the dermal compartment
compared with epidermal layers, and was significantly higher for CCRL2. If CMKLR1 and
CCRL2 serve as chemerin receptors in skin, then skin chemerin levels may be diminished in the
absence of these receptors. As demonstrated in Fig. 1F, skin chemerin levels tended to be lower in
CMKLR1 KO and CCRL2 KOmice and were the lowest in mice with a combined deletion of
CMKLR1 and CCRL2 (CMKLR1/CCRL2 KO) compared toWTmice. On the other hand, plas-
ma chemerin levels showed the opposite trend and were highest in CMKLR1/CCRL2 KOmice
(Fig. 1G). This is consistent with a previous report indicating elevated chemerin levels in CCRL2
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KOmice [21] and is a general phenomenon common to cognate receptor-deficient mice [37].
Together, these data suggest that chemerin is sequestered in skin by CMKLR1 and CCRL2.
We next evaluated chemerin and chemerin receptor levels in human skin. Similar to mouse
skin, chemerin levels were significantly higher in human epidermis compared with dermis
(Fig. 2A and B). On the other hand, there were no significant differences in human epidermal
vs. dermal expression of CMKLR1, CCRL2 and GPR1 (Fig. 2C-E).
Regulation of chemerin expression in keratinocytes by acute phase
mediators
To facilitate our studies investigating the mechanisms regulating chemerin expression in skin
we generated pseudo-stratified, highly differentiated human epidermal tissue in vitro. In
Fig 1. Chemerin and chemerin receptor expression in mouse skin. Chemerin mRNA expression (A), chemerin protein expression in tissue lysates (B),
chemerin receptor (CMKLR1, CCRL2, GPR1) mRNA expression (C-E), or chemerin protein expression in skin homogenates (F) and chemerin expression in
plasma (G) was measured in the indicated tissues isolated from C57BL/6 mice (A-E) or the indicated mice on BalbC backround (F-G) by RT-QPCR and
ELISA. The expression data of the indicated genes was normalized to cyclophilin A and RPL13A, and presented relative to liver as the mean ± SEM, n = 4–5
different mice (A, C-E). The amount of chemerin protein in plasma, or skin lysates and homogenates normalized to total protein is shown as the mean ± SEM,
n = 4 (B), or n6 mice (F-G). Statistical significance is indicated by asterisk(s); *p<0.05, **p<0.01, by ANOVA followed by a Bonferroni post hoc test.
doi:10.1371/journal.pone.0117830.g001
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Fig 2. Chemerin in healthy human skin is primarily expressed in the epidermis. Chemerin mRNA
expression (A), chemerin protein expression in tissue lysates (B), and chemerin receptor (CMKLR1, CCRL2,
GPR1) mRNA expression (C-E), was measured in the indicated tissues isolated from healthy human donors.
Total RNA was subjected to RT-QPCR. The expression data of the indicated genes was normalized to B2M
and GAPDH, and presented relative to skin (A, C-E). The amount of chemerin in skin lysates, normalized to
total protein was determined by ELISA (B). The mean of n = 6 (A, C-E) or n = 8 (B) different donors ± SEM is
shown. Statistical significance between epidermis and dermis is shown by asterisk(s); *p<0.05, **p<0.01,
by ANOVA followed by a Bonferroni post hoc test.
doi:10.1371/journal.pone.0117830.g002
Chemerin Regulation in Epidermis
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contrast to keratinocyte monolayers that do not fully recapitulate the multilayered differentia-
tion of epidermis and express little-to-no chemerin ([27] and data not shown), this 3D tissue
closely resembles the epidermis, and keratinocytes in these 3D cultures express high levels of
chemerin Figs. 3 & 4. Importantly, the polarized nature of skin keratinocytes in this model al-
lows for the anatomical segregation of epidermal responses. We applied cytokines to the baso-
lateral compartment to mimic epidermal cytokine exposure resulting from immune cells
infiltrating the skin [38,39,40,41].
We first asked if local chemerin synthesis in the skin was induced by acute phase mediators
such as oncostatin M (OSM) and IL-1β, which mobilize protective acute phase reactants. Cells
and conditioned media from cultured human skin equivalents were collected 24–48h after
basolateral treatment, since the effect of OSM on gene expression is typically most profound at
these time points [31,42,43,44]. Treatment with OSM, IL-1β, and the combination resulted in
either a tendency to higher chemerin levels or statistically significant upregulation of chemerin
mRNA and protein at both time points (Fig. 3). Chemerin production was the highest in re-
sponse to OSM + IL-1β at 24h (7.3-fold increase over control by RNA analysis, and 2-fold by
secreted protein analysis), suggesting additive effects (Fig. 3).
Fig 3. Psoriasis-associated cytokines downregulate chemerin and acute phase cytokines upregulate
chemerin expression in epidermis.Normal keratinocytes grown in 3D culture were treated with the
indicated factors for 24 (A-B) or 48h (C-D). Total RNA was subjected to RT-QPCR. Relative expression of
stimulated cells over control is shown as the mean ±SD from five-nine independent experiments (A, C).
Levels of secreted chemerin were determined in parallel in conditioned media by ELISA. Data show the
mean ±SD from five-nine independent experiments (B, D). Statistical significance between control and the
treated cells is shown by asterisk; *p<0.05 by ANOVA followed by a Bonferroni post hoc test.
doi:10.1371/journal.pone.0117830.g003
Chemerin Regulation in Epidermis
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Regulation of chemerin expression in keratinocytes by “psoriatic
cytokines”
IL-17 and IL-22 drive keratinocyte pathology in psoriasis [39,40,41]. We next asked if IL-17
and Il-22 applied to the basolateral compartment affected chemerin expression/secretion in the
epidermis model. IL-17 and IL-22 were equally efficacious in downregulating chemerin expres-
sion at 48h (on average 2.5-fold compared with untreated controls), and when used together
exhibited an additive effect (4.3-fold reduction). Consistent with IL-17- and IL-22-mediated in-
hibition of chemerin RNA expression, secreted protein tend to be diminished (Fig. 3C and D).
Together, these data suggest that chemerin is a regulatory target of IL-17 and IL-22 in
epidermal tissue.
Regulation of chemerin expression in human keratinocytes and mouse
skin by bacteria
Since chemerin has antimicrobial activity in normal human skin, we next asked if its expression
was modulated by bacteria exposure in the epidermal model (apical side treatment). We select-
ed two bacteria strains, E. coli and S. aureus, both of which are susceptible to chemerin-depen-
dent killing, although with different potencies (MIC = 3.1–6.3μg/ml vs. 12.5μg/ml for E. coli
and S. aureus, respectively) [25]. E. colimarkedly upregulated chemerin RNA expression (~7-
fold), (Fig. 4A) and secreted protein (75±20 ng/ml versus 43±12 ng/ml in untreated cultures)
at 24h (Fig. 4B). The effect of E. coli remained significant although somewhat diminished by
48h (Fig. 4C and D). Interestingly, compared with live bacteria, heat-killed counterparts trig-
gered no significant effects on chemerin expression or secretion. This may be attributed to the
ability of live microorganisms to replicate and/or express specialized stimulating factors. At
least part of the stimulatory effect of E. coli was mediated by soluble factors, most likely LPS, as
LPS alone significantly increased chemerin mRNA at 24h. Compared with E. coli, S. aureus
was more effective in boosting chemerin expression, resulting in 10-fold and 8-fold induction
of chemerin mRNA levels at 24h and 48h, respectively (Fig. 4A and C). The effect of S. aureus
on chemerin gene expression was reflected in secreted chemerin protein levels, which increased
from 43±12 to 123±24 ng/ml following 24h co-incubation, and from 53±17 to 185±47 ng/ml
after 48h incubation with the bacteria (Fig. 4B and D). We hypothesized that since chemerin is
more potent in killing E. coli compared with S. aureus, the keratinocytes in the in vitro culture
may have been exposed to lower doses of E. coli than S. aureus. This may in turn result in the
appearance of a more robust induction of chemerin by S. aureus. To address this, we treated S.
aureus with bacteriostatic doses of ampicilin. This treatment resulted in comparable numbers
of CFU for E. coli and S. aureus during their incubation with keratinocytes, and did not signifi-
cantly change the chemerin levels in control keratinocytes (data not shown). There was no sig-
nificant difference in epidermal chemerin induction by S. aureus vs. S. aureus treated with
ampicillin, both of which were more effective than E. coli (Fig. 4A-D). These data imply that a
S. aureus-intrinsic component stimulates higher levels of chemerin expression than E. coli, and
that the effect is unrelated to differential microbe-specific killing potencies of chemerin. In ad-
dition, live S. aureus was ~3-fold more effective than heat-killed counterparts in inducing che-
merin (Fig. 4A and C).
Since the effect of live S. aureus on chemerin expression dominated over other factors, we
investigated this effect more closely by immunohistochemistry. S. aureus-treated and untreated
skin equivalents appeared similar by microscopic analysis of H&E stained sections (Fig. 4E).
Chemerin was present in all strata, with the exception of stratum granulosum. However, che-
merin staining was more intense in all epidermal strata in S. aureus-treated skin vs. control,
most notably in the stratum basale, suggesting that the elevated chemerin protein levels
Chemerin Regulation in Epidermis
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detected in conditioned media likely result from its secretion primarily by proliferating kerati-
nocytes (Fig. 4E).
Regulation of CMKLR1, CCRL2 and GPR1 expression in human
epidermis equivalents
We next evaluated the expression of chemerin receptors in skin equivalents in response to cyto-
kines and bacteria. CMKLR1 mRNA levels were significantly upregulated following 24h treat-
ment with IL-1β and the combination of IL-1β and OSM, while IL-17 and/or IL22 had no
effect (Fig. 5A). Of the cytokines tested, only IL-1β had a significant effect on CMKLR1 levels
at 48h (Fig. 5B) Likewise, CCRL2 and GPR1 were significantly upregulated only by IL1β or
IL1β+OSM at the 24h time point, and by IL1β at the 48h time point in the case of CCRL2
Fig 4. Bacteria upregulate chemerin expression in epidermis. Keratinocytes were treated with the indicated factors for 24 (A, B, E) or 48h (C, D). Total
RNA was subjected to RT-QPCR. Relative expression of stimulated cells over control is shown as the mean ±SD from five-nine independent experiments (A,
C). Levels of secreted chemerin were determined in parallel in conditioned media by ELISA. Data show the mean ±SD from five-nine independent
experiments (B, D). Statistical significance between control and the treated cells is shown by asterisk; *p<0.05 by ANOVA followed by a Bonferroni post hoc
test. E. c., E. coli; HK, heat-killed; SN, supernatant; S. a., S. aureus; A, ampicillin-treated. Microscope images of keratinocytes stained with hematoxilin and
eosin (H&E) and fluorescence microscope images of keratinocytes stained for chemerin (chem) or control rabbit Abs (cAb) (red), with Hoechst counterstain
to detect cell nuclei (blue). Scale bar = 10 μm. Data are representative of three different donors. SC, stratum corneum, SG, stratum granulosum, SS, stratum
spinosum, SB stratum basale, TM transwell membrane (E).
doi:10.1371/journal.pone.0117830.g004
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(Fig. 5). CCRL2 was also significantly dowregulated by IL22 at 48h, whereas GPR1 expression
was not altered (Fig. 5B).
CCRL2 and GPR1 RNA expression was significantly downregulated by 24h-treatment with
E. coli and E. coli products, and to a lesser extent by S. aureus, whereas levels of CMKLR1 were
unaffected (Fig. 6A). Interestingly, at 48h, CCRL2 expression was significantly induced by live
S. aureus but not by E. coli and its derivatives (Fig. 6B). A similar trend was noted for
CMKLR1. Taken together, these data suggest that different regulatory mechanisms underlie
the expression of each of the chemerin receptors in human epidermis.
Fig 5. Expression of chemerin receptors in human skin equivalents treated with cytokines.
Keratinocytes were treated with the indicated factors for 24h (A) or 48 h (B). RT-QPCRwas performed and
the expression data were normalized to cyclophilin A and expressed relative to unstimulated cells. Mean ±
SD of 5–8 independent experiments is shown. Statistical significance comparing cytokine-treated cells vs.
untreated cells (* p<0.05) was determined by ANOVA followed by a Bonferroni post hoc test.
doi:10.1371/journal.pone.0117830.g005
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Fig 6. Expression of chemerin receptors in human skin equivalents treated with bacteria.
Keratinocytes were treated with the indicated factors for 24h (A) or 48 h (B). RT-QPCRwas performed and
the expression data were normalized to cyclophilin A and expressed relative to unstimulated cells. Mean ±
SD of 5–7 independent experiments is shown. Statistical significance comparing cytokine-treated cells vs.
untreated cells (* p<0.05) was determined by ANOVA followed by a Bonferroni post hoc test.
doi:10.1371/journal.pone.0117830.g006
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Regulation of chemerin and its receptors by bacteria in mouse skin in
vivo
Due to the pronounced elevation of chemerin levels by bacteria and the differential effects of E.
coli and S. aureus on chemerin receptor expression in human skin equivalents, we next asked if
these responses occur in vivo. Mice were ectopically treated with E. coli or S. aureus, and the
skin analyzed for chemerin and chemerin receptor expression 24h later. Both E. coli or S. aure-
us significantly upregulated chemerin mRNA and chemerin protein levels in skin lysates
(Fig. 7A and B). However, similar to human skin equivalents, S. aureus seemed to be more po-
tent in inducing chemerin expression compared with E. coli, although this trend did not reach
statistical significance. S. aureus significantly increased CMKLR1 and GPR1 RNA expression
in the skin (Fig. 7C and E), while E. coli significantly increased the expression of CCRL2 and
GPR1 (Fig. 7D &E). Together, these data suggest that the expression of chemerin and its recep-
tors are influenced in distinct fashion by cutaneous microbes.
Chemerin is required for maximal bactericidal effects in vivo
Given the significant local induction of chemerin in the skin in response to bacterial challenge,
we next asked if chemerin controls bacterial burden in skin. Chemerin-deficient mice and wild
type controls were topically infected with S. aureus, and the bacterial load recovered from the
skin surface 24h later was measured by colony-forming assay. Chemerin-deficient mice har-
bored at least 10-fold higher bacterial levels compared to WT (Fig. 8). These data suggest that
chemerin plays a key role in restricting bacteria growth in skin.
Discussion
Here we report on previously unappreciated regulators of chemerin synthesis in the epidermis
that link chemerin expression to both clinical findings in psoriasis and antimicrobial functions
of chemerin in skin.
First, treatment of model epidermis with IL-17 and IL-22 recapitulate the reduction in che-
merin levels reported in affected skin from psoriasis patients. Although the nature and signifi-
cance of chemerin downregulation in lesional psoriatic skin remains obscure, we reasoned that
chemerin expression might be affected by the same mediators that drive the disease processes.
Genetic studies, usage of therapeutic antagonists, as well as recently developed imiquimod-
based mouse model of psoriasis, established a pivotal role for the IL-17 as a driver in skin in-
flammation in psoriasis [39,45]. In addition, IL-22 has emerged as a key regulator of keratino-
cyte hyperplasia in this disorder [40,46,47]. Deficiencies in either, IL-17 or IL-22 result in
partial protection, whereas absence of both IL-17- and IL-22-mediated responses confers al-
most total protection against the disease, suggesting additive or synergistic effects of these cyto-
kines in the development of skin changes. Keratinocytes appear to be one of the main targets of
IL-17 and IL-22 in psoriatic skin [39,40]. This is supported by the finding that the absence of
IL-17 or IL-22 correlates with marked reduction in epidermal thickening along with dimin-
ished numbers of skin infiltrating immune cells in vivo. Moreover, keratinocytes respond to
these cytokines in vitro with a psoriatic-like gene expression signature that includes production
of proinflammatory cytokines, chemokines, complement components and antimicrobial pep-
tides [39,40,47]. Our work indicates that chemerin may be a regulatory target of IL-17 and IL-
22 in epidermis, potentially influencing skin cell responses in psoriasis.
Second, we identified two different chemerin regulation patterns in response to cytokines
that are elevated or induced in psoriatic skin. In contrast to IL-17 and IL-22, which suppressed
chemerin expression, OSM and IL-1β significantly increased chemerin production, despite the
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fact that all four cytokines are potent keratinocyte activators with potential roles in the patholo-
gy of psoriasis [38,43,48]. IL-1β has been assigned a prominent function in various aspects of
cutaneous inflammation, for example, as a key contributing factor to the development and
maturation of IL-17 secreting T cells, or in the recruitment of neutrophils to psoriatic skin
[49,50,51]. On the other hand, OSM was linked to the pathology of psoriasis through its ability
to inhibit expression of keratinocyte differentiation markers, including filaggrin and loricrin,
which are decreased in the skin of psoriatic patients, or through inducing AMPs in reconsti-
tuted epidermis, such as psoriasin (S100A7), calgranulin C (S100A12) and β-defensin 2, which
are strongly associated with psoriasis [38,43,52]. Although these OSM-mediated skin alter-
ations suggest a pathogenic role of OSM in the disease, this cytokine may also contribute to at-
tenuating the pathology, depending, for example, on the phase of the disease. This is supported
by its well-defined role as an acute phase mediator as well as the observation that in reconsti-
tuted epidermis, OSM also downregulated sets of genes regarded as pro-inflammatory in psori-
asis, such as Th1-type signaling molecules [43]. The opposing effects of OSM and IL-1β
compared with IL-17 and IL-22 on chemerin production in keratinocytes suggests different
roles for the former in regulating chemerin-mediated skin changes. Notably, in contrast to IL-
17 and IL-22, which had no effect or downregulated the chemerin receptors, IL-1β and to the
lesser extend OSM increased expression of the receptors, suggesting that chemerin might have
a particularly strong impact on skin pathophysiology when IL-1β and/or OSM are present.
Since the epidermal disruption that occurs in psoriasis may lead to a compensatory engage-
ment of cytokines involved in restoration of homeostasis, such as acute phase mediators-OSM
and IL-1, chemerin and chemerin receptor levels that rise in response to OSM and IL-1βmay
serve to improve skin conditions.
Fig 7. Bacteria controls the expression of chemerin and its receptors in vivo.Mice were ectopically
treated with S. aureus, E coli or PBS (control) for 24h. The skin exposed to the treatment was then collected
for RNA and protein isolation. Chemerin and chemerin receptor message was determined by RT-QPCR. The
expression data was normalized to cyclophilin A and presented relative to PBS-treated skin (A, C-E). The
amount of chemerin in skin lysates, normalized to total protein was determined by ELISA (B). Data are shown
as the mean ±SEM from six mice in each group. Statistically significant differences between PBS-treated and
bacteria-treated mice is indicated by an asterisk (*, p<0.05; ANOVA followed by a Bonferroni post hoc test).
doi:10.1371/journal.pone.0117830.g007
Fig 8. Chemerin is bactericidal in vivo. Chemerin–deficient (ChemKO) andWTmice were ectopically
treated with S. aureus. Bacteria were retrieved from skin 24h later, and presented as a % of input inoculum.
Each data point represents one experiment and a horizontal line indicate the mean value in each group.
*p<0.05, by t test.
doi:10.1371/journal.pone.0117830.g008
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Third, our findings indicate that the epidermis is a functional bacteria-responsive anatomic
site for chemerin production. The major function of the epidermis is to provide a barrier
against the external environment that includes a variety of pathogenic microorganisms. Our
data suggest that keratinocytes respond to microbial stimuli with chemerin synthesis. They
also indicate that the epidermis, through upregulation of CCRL2 or CMKLR1, is likely to re-
spond to chemerin in an autocrine manner when challenged by specific bacteria strains.
Whereas E. coli and S. aureus both increased chemerin expression in human skin equivalents
in vitro as well as mouse skin in vivo, chemerin receptor expression appeared to be differential-
ly regulated by these bacteria strains. Most striking was a stimulatory role of S. aureus but not
E. coli on CCRL2 expression in human skin equivalents. Restricting keratinocyte response to
upregulation of chemerin but not CMKLR1 or CCRL2, as was the case for E. coli-mediated
stimulation, may be a mechanism that diminishes CCRL2-mediated accumulation of chemerin
on keratinocyte surfaces or CMKLR1-mediated signaling in keratinocytes, allowing free che-
merin to act as an AMP. In contrast, S. aureus has the potential to contribute to epidermal biol-
ogy by virtue of its reciprocal induction of chemerin and chemerin receptor expression.
Whereas the secretion of chemerin by S. aureus-stimulated keratinocytes may contribute to es-
tablishing a biochemical shield to microbial colonization of skin by other bacteria, upregulation
of chemerin receptors might foster chemerin-mediated, yet-to- be-identified functional
changes in mammalian skin.
S. aureus and E. coli are likely to deploy various mechanisms to affect production of che-
merin and chemerin receptors in keratinocytes. These may include soluble factors and/or non-
secreted bacterial components, such as structures of the bacterial wall that differ substantially
between these two microorganisms. Killing of either bacteria with heat, diminished chemerin
production in keratinocytes, suggesting that bacteria viability is an important determinant as-
sociated with chemerin synthesis. A new concept has emerged that the recognition of so-called
vita-PAMPs (viability associated pathogen-associated molecular patterns) that are present only
in viable bacteria elicits unique responses [53]. These include bacterial messenger RNA. The
stimulation of chemerin production by vita-PAMPs may explain the differential potency of
live and dead bacteria to regulate chemerin expression in keratinocytes. Since chemerin synthe-
sis in reconstituted human epidermis is also triggered to some extent by bacterial supernatants,
soluble factors may also be involved in promoting chemerin synthesis in keratinocytes.
Together, our findings reveal an inherent ability of human and mouse epidermis to express
high levels of chemerin. Our previous work demonstrated the potent antimicrobial activity of
human keratinocyte-derived chemerin [25], and our present study shows substantially dimin-
ished antimicrobial activity in chemerin-deficient mice. Thus, elevation of chemerin levels by
acute phase cytokines and specific bacteria strains, and downregulation by cytokines associated
with psoriasis may reflect a programmed response to skin challenge that regulates defensive
functions of this organ.
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